PRESS KITCHESS



00 CONTENTS



01	THE COMPANY	3
	General information	4
	Business divisions	5
	Greiner Bio-One International GmbH	
02	KEY FACTS	7
		0
	Greiner Bio-One International GmbH	
	Company headquarters	9
03	FINANCIAL YEAR 2022	10
	Management change	11
	Innovative product solutions	
	Investments	
	Business development in 2023	
	Outlook for 2024	
	Outiou(101 Z0Z¬	

04	MILESTONES	16
	Success story of Greiner Bio-One	17
05	PRODUCTS	18
	Preanalytics Portfolio	19
	BioScience Portfolio	21
06	FURTHER INFORMATION	23
	Additional links	24
	Contact partners	25



01



© Greiner Bio-One GmbH 2024 page 3/26

01 THE COMPANY



GENERAL INFORMATION

BUSINESS UNITS

GREINER BIO-ONE INTERNATIONAL GMBH

GENERAL INFORMATION

Greiner Bio-One specialises in the development, production and distribution of high-quality plastic laboratory products.

The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries.

The medical technology company is divided into the three business divisions Preanalytics, BioScience and Mediscan.

As an Original Equipment Manufacturer (OEM), Greiner Bio-One is also a solid partner for industry clients working in pharmaceuticals, biotechnology, diagnostics and medical technology and offers customised design development and production processes.

© Greiner Bio-One GmbH 2024

01 THE COMPANY



GENERAL INFORMATION

BUSINESS UNITS

GREINER BIO-ONE INTERNATIONAL GMBH

BUSINESS UNITS

The **Preanalytics** business unit, with headquarters in Kremsmünster (Austria), develops and produces innovative collection systems for human and veterinary blood, urine and saliva samples, with the aim of making day-to-day, routine tasks in hospitals, laboratories and doctors' practices easier and safer. This division also covers software solutions (Tracie Healthcare Solutions) which ensure greater efficiency and patient safety in the preanalytical process.

Greiner Bio-One's **BioScience** unit, with headquarters in Frickenhausen (Germany), is one of the leading suppliers with a wide range of specialist products for the cultivation and analysis of cell and tissue cultures. Based on decades of experience in the cryopreservation of samples, Greiner Bio-One also offers solutions for automated storage systems in biobanks. In addition, the division also develops and produces microplates for high-throughput screening, which ensure the quickest and most efficient testing of substances and materials in both industry and research.


Greiner Bio-One's third business unit is **Mediscan**, a wholly-owned subsidiary of Greiner Bio-One International with headquarters in Kremsmünster (Austria). Mediscan is a skilled service provider in the field of sterilisation of medical products and food packaging, and also specialises in improving the function of plastics and semiconductors using ionising radiation.



Innovative collection systems for human and veterinary samples from blood, urine and saliva



Special products for the cultivation and analysis of cell and tissue cultures



Sterilization by means of ionizing radiation

© Greiner Bio-One GmbH 2024 page 5/26

01 THE COMPANY



GENERAL INFORMATION

BUSINESS UNITS

GREINER BIO-ONE INTERNATIONAL GMBH

	o-One nal GmbH (AT)	100%
ner Bio	-One GmbH (AT)	100%
Greine	r Bio-One Hungary Kft. (HU)	100%
Greine	r Bio-One North America, Inc. (US)	100%
Greine	r Bio-One North America Sales Corp. (US)	100%
Greine	r Bio-One France S.A.S. (FR)	100%
	er Bio-One Brasil Produtos Medicos talares Ltda. (BR)	99.99%
	99.99%	
	r Bio-One Brasil Service Tech Sistemas, os E Servicos para saude Ltda. (BR)	< 0.01%
Greine	r Bio-One VACUETTE Schweiz GmbH (CH)	100%
Greine	r Bio-One (Thailand) Ltd. (TH)	100%
Grein	er Bio-One Suns Co., Ltd. (CN)	100%
В	eijing GBO Suns Medical Devices Co., Ltd. (CN)	100%
Greine	r Bio-One Shanghai, Co.Ltd. (CN)	100%
Greine	r Bio-One India Private Limited (IN)	99.99%
	r Bio-One Turkey Laboratuvar ri Limited Sirketi (TR)	100%
Greine	r Bio-One Italia S.R.L. (IT)	100%
GREIN	IER BIO-ONE ESPANA S.A. (ES)	100%
	ACUETTE PORTUGAL Importacao e Exportaca le Material Hospitalar S.A. (PT)	ao 100%
Vigme	ed AB (SE)	100%
Grein	er Bio-One Singapore Pte. Ltd. (SGP)	100%
Tracie	Healthcare Solutions GmbH (DE)	81.9%
Grein	er Bio-One MEA FZ-LLC (AE)	100%
iner Bi	o-One GmbH (DE)	100%
Greine	r Bio-One Ltd. (UK)	100%
Greine	r Bio-One Co. Ltd. (JP)	100%
Grein	er Bio-One B.V. (NL)	100%
C	Greiner Bio-One nv/sa (BE)	100%
Mediscan GmbH (AT) 100%		
liscan G	imbH & Co. KG (AT)	100%

© Greiner Bio-One GmbH 2024 page 6/26



02



© Greiner Bio-One GmbH 2024 page 7/26

02 KEY FACTS



GREINER BIO-ONE INTERNATIONAL GMBH

GREINER BIO-ONE
INTERNATIONAL GMBH

COMPANY HEADQUARTERS



HEADQUARTERS

Kremsmünster, Austria

MANAGEMENT


CEO Ilke Panzer

LOCATIONS

29 subsidiaries

SALES PARTNERS

Distributors in more than 100 countries





2,659

2023

© Greiner Bio-One GmbH 2024 page 8/26



COMPANY HEADQUARTERS

GREINER BIO-ONE
INTERNATIONAL GMBH

COMPANY HEADQUARTERS



Greiner Bio-One GmbH Preanalytics (Kremsmünster, Austria)

GREINER BIO-ONE GMBH PREANALYTICS

OFFICE LOCATION

Kremsmünster, Austria

EMPLOYEES

679

PRODUCTION

Preanalytics products

MANAGEMENT

Thomas Scheurecker Georg Heftberger Kruno Obrovac



Greiner Bio-One GmbH BioScience (Frickenhausen, Germany)

GREINER BIO-ONE GMBH BIOSCIENCE

OFFICE LOCATION

Frickenhausen, Germany

EMPLOYEES

408

PRODUCTION

BioScience products

MANAGEMENT

Bernd Klingel

© Greiner Bio-One GmbH 2024 page 9/26



03

FINANCIAL YEAR 2023

© Greiner Bio-One GmbH 2024 page 10/26



MANAGEMENT CHANGE

MANAGEMENT CHANGE

INNOVATIVE PRODUCT SOLUTIONS

INVESTMENTS

BUSINESS DEVELOPMENT IN 2023

OUTLOOK FOR 2024

In the summer of 2023, a decision was made to place the division's management in new hands. Manfred Stanek, COO of Greiner AG, also temporarily assumed the role of CEO of Greiner Bio-One from the previous division manager, Rainer Perneker.

Ilke Panzer took over as the new division manager on February 1, 2024. She was born in Germany and has spent most of her career in the USA. Most recently, she worked as a freelance consultant in healthcare innovation. Having gained leadership experience at Assurance Laboratories LLC, BloodCenter Wisconsin, and Johnson & Johnson, she can contribute extensive knowledge from the healthcare and pharmaceutical industries.

She began her career at General Electric, where her roles included General Manager of the Global Ultrasound business. Panzer studied engineering, computer and systems engineering at the University of Connecticut, USA, and at the National Technological University in Fort Collins, Colorado. She has been a member of the Supervisory Board of the German pharmaceutical and laboratory supplier Sartorius AG since 2017.

"We want to contribute to remarkable successes in medicine and make a real difference for users and patients."



Ilke Panzer, CEO Greiner Bio-One International GmbH
(c) Silvia Wittmann

© Greiner Bio-One GmbH 2024 page 11/26



INNOVATIVE PRODUCT SOLUTIONS

MANAGEMENT CHANGE

INNOVATIVE PRODUCT SOLUTIONS

INVESTMENTS

BUSINESS DEVELOPMENT IN 2023

OUTLOOK FOR 2024

The new VACUETTE® CAT serum fast separator tube combines the speed of a plasma tube with the quality of serum in terms of the red blood cells remaining after centrifugation. The turn-around time (TAT; time between blood collection and obtaining the results) is significantly shortened by the new tube. Thanks to the short clotting time of just five minutes and the subsequent five-minute centrifugation, analysis can begin after ten short minutes and treatment started more quickly. The inside of the shatterproof tube is coated with a mixture of blood-clotting activator and thrombin. After centrifugation, the added gel forms a stable barrier between the serum and the solid components. The thrombin in the additive accelerates the clotting process.

The tried and proven ThinCert® cell culture inserts are successfully used worldwide for demanding cell and tissue culture applications. The current portfolio consists of individual membrane-based cell culture inserts for 6, 12, or 24 well plates. The new 96 well HTS variant allows for automation, increases throughput and thus saves time and costs compared to the single-insert solutions. The new ThinCert® HTS insert product variants with pore sizes of 3 µm or 8 µm are particularly suitable for migration and invasion studies, which play a decisive role in physiological and pathological processes such as the migration of immune cells, wound healing processes, or the metastasis of tumor tissue.



VACUETTE ® CAT Serum Fast Separator Tubes



ThinCert® 96-well HTS insert

© Greiner Bio-One GmbH 2024 page 12/26



INVESTMENTS

MANAGEMENT CHANGE

INNOVATIVE PRODUCT SOLUTIONS

INVESTMENTS

BUSINESS DEVELOPMENT IN 2023

OUTLOOK FOR 2024

Greiner Bio-One's production volumes and demand for sterilization service providers have increased since the last site expansion in 2015. This is why an additional plant for sterilizing medical products and food packaging and refining plastics and semiconductors is being built adjacent to the existing plant in Kremsmünster. The plant technology meets the latest standards, has been technologically enhanced compared to the predecessor model and once again combines two different treatment technologies in a single plant that is scheduled to go into operation in mid-2024. Its future capacity will make it Europe's largest sterilization facility.

A new warehouse and office building was built at the sales branch in the UK in 2023. The new building, located just 800 meters away from the previous site, has an area of 53,500 square meters and boasts twice as much storage space as the old location. These new warehouse facilities and improved incoming and outgoing goods processes ensure better logistics management. In moving to the new building, Greiner Bio-One is laying the foundations for further growth. The new site has been fully operational since the start of 2024.



Europe's largest sterilization plant



New warehouses and office buildings for Greiner Bio-One UK

© Greiner Bio-One GmbH 2024 page 13/26



BUSINESS DEVELOPMENT IN 2023

MANAGEMENT CHANGE

INNOVATIVE PRODUCT SOLUTIONS

INVESTMENTS

BUSINESS DEVELOPMENT IN 2023

OUTLOOK FOR 2024

Last year, Greiner Bio-One 637 million euros in sales revenue, a decline of 8.1 percent.

As the COVID-19 pandemic subsided and disrupted supply chains were restored, customers across the industry built up massive inventories, which in turn led to a decline in current demand. The business unit is also challenged by high inflation and interest rates, which have significantly driven up production costs at its main facilities.

Incoming orders in Preanalytics declined slightly but remained at a high level. In the BioScience unit, Greiner Bio-One continued to feel the effects of the cost-cutting measures taken by many research institutes: projects were postponed and fewer consumables were needed.

© Greiner Bio-One GmbH 2024 page **14**/26



OUTLOOK FOR 2024: PROFITABLE GROWTH

MANAGEMENT CHANGE

INNOVATIVE PRODUCT SOLUTIONS

INVESTMENTS

BUSINESS DEVELOPMENT IN 2023

OUTLOOK FOR 2024

Greiner Bio-One will continue to focus on profitable growth in the current year in order to be able to finance important projects and investments. In the Preanalytics and BioScience business units, Greiner Bio-One is building on its core products to further strengthen its position in the market. In addition to its home markets in Europe, the company sees great potential for further expansion of its global market share, particularly in Asia and the USA. The current challenging market situation notwithstanding, we will complete the ongoing infrastructure investments in Brazil and Austria (Kremsmünster) as well as the capacity expansions in individual product groups in both business units (TC tubes, roller bottles, HTS plates, and blood tubes). These measures will help to support the expected upturn in 2024.

Greiner Bio-One will continue to focus on equipping the company and its employees for the demands of the future and thus for sustainable growth in 2024. In this context, Greiner Bio-One also established a Sustainability Council to implement the

Group-wide topics and meet related customer needs, improve product sustainability and reduce Scope 3 emissions.

© Greiner Bio-One GmbH 2024 page 15/26



04

4 MILESTONES

© Greiner Bio-One GmbH 2024 page 16/26

04 MILESTONES



SUCCESS STORY OF GREINER BIO-ONE

SUCCESS STORY
OF GREINER BIO-ONE

Company founded

as Greiner Labortechnik (now: Greiner Bio-One)

Greiner starts
life in Nürtingen
(Germany) with
the manufacture
of the first plastic
Petri dishes.

Greiner develops the world's first 1536 Well

Microplate.
The plates are used to test substances for manufacturing

medication.

Introduction of the first safety products

safety
products
in the
VACUETTE®
line.

Through its acquisition of 3D cell culture assets from Nano3D Biosciences, Inc., Greiner Bio-One becomes a leading international provider in the field of three-dimensional cell cultivation.

evoprotect
represents the
next stage in
blood collection.
It protects the
user from the risk
of needlestick
injuries and
provides
substantial
support for safe
blood collection.

VACUFTTF®

Greiner Bio-One celebrates its anniversary. Even after 60 years, we stand more than ever for technology, quality and global presence.

The world's

first evacuated blood collection system made of only plastic is launched. Many further developments follow in the next few years.

Greiner
Labortechnik
already has an
international
footing and
expands further.
In 2000, the
company is
rebranded

from Greiner Labortechnik to Greiner Bio-One. Incorporation of
Mediscan
into the Greiner
Bio-One Group.

With the rapid
development of
the VACUETTE®
virus stabilization
tube and a focus
on COVID-19
relevant products,
Greiner Bio-One is
making
a key contribution

a key contribution to the conquest of the pandemic. On 1 March 2022,
Tracie Healthcare
Solutions, a
start-up from
Bridgemaker and
Greiner Bio-One,
is founded. Tracie
digitizes the entire

preanalytical sample process and reduces the error rate.

© Greiner Bio-One GmbH 2024



© Greiner Bio-One GmbH 2024 page 18 / 26



PREANALYTICS PORTFOLIO

PREANALYTICS PORTFOLIO

BIOSCIENCE PORTFOLIO Greiner Bio-One offers an extensive product portfolio not only for routine procedures but also for specialist areas of application in pre and postanalytics. The portfolio ranges from evacuated blood collection tubes, urine tubes and containers as well as many other accessories and safety products, through to ESR (erythrocyte sedimentation rate) systems, transport and disposal containers, and a diverse range of auxiliary devices such as decapping instruments.

COLLECTION SYSTEMS FOR BLOOD AND URINE

The VACUETTE® line comprises innovative sample collection systems for blood, urine and saliva. The collection tubes contain a pre-dosed vacuum and an additive which is required for further processing. All of our VACUETTE® tubes make sample collection easy, ensure the same mixing ratio every time and guarantee reliable test results.

MiniCollect® offers a gentle way to collect small blood samples for a wide range of analyses. The system is perfectly suited for young children, geriatric patients as well as patients with fragile veins.



VACUETTE® tubes



MiniCollect® system

© Greiner Bio-One GmbH 2024 page 19/26



PREANALYTICS PORTFOLIO

BIOSCIENCE PORTFOLIO

SAFETY PRODUCTS

Safety is our top priority! The risk of injury and contamination can be significantly reduced by using safety products such as cannulae with protective caps, safety tube holders or safety blood collection sets for sample collection.

ACCESSORIES

The Greiner Bio-One range for the field of preanalytics comprises additional accessories for venous blood collection (tube holders, blood collection sets and cannulae, snap caps, etc.) and capillary blood collection (carrier tubes, funnels, etc.), urine collection (urine sets, cups, collection containers, etc.), as well as accessories for disposal boxes and transportation

TRANSPORT, DISPOSAL AND DEVICES

In order to ensure the safe transportation of samples, Greiner Bio-One offers transport boxes and containers. The range also includes a diverse selection of decapping and ESR devices as well as disposal boxes in a variety of sizes to suit different requirements.



VACUETTE® safety products



VACUETTE® accessories



VACUETTE® transport line

© Greiner Bio-One GmbH 2024 page 20/26



PREANALYTICS PORTFOLIO

BIOSCIENCE PORTFOLIO

BIOSCIENCE PORTFOLIO

Greiner Bio-One's Bio Science division is one of the leading providers of specialist products for the cultivation and analysis of cell and tissue cultures. Based on decades of experience in the cryopreservation of samples, Greiner Bio-One also offers solutions for automated storage systems in biobanks. In addition, the division also develops and produces microplates for high-throughput screening, which ensure the quickest and most efficient testing of substances and materials in both industry and research.

PRODUCTS FOR CELL CULTURE, MASS CELL CULTURE AND 3D CELL CULTURE

With the CELLSTAR* product line, Greiner Bio-One BioScience develops and sells products for the cultivation, storage and separation of cells as well as for specific applications in medical, pharmaceutical and biotechnological research. In addition, the company offers solutions for the automation and scale-up of mass cell cultures as well as for 3D cell cultivation.



CELLSTAR° cell culture flasks

© Greiner Bio-One GmbH 2024 page 21/26



PREANALYTICS PORTFOLIO

BIOSCIENCE PORTFOLIO

PRODUCTS FOR HIGH-THROUGHPUT SCREENING (HTS)


For decades, Greiner Bio-One has been producing plastic microplates that are used in laboratories all over the world for diagnostics and research. Microplates enable quick, automated analysis of a range of substances. It is this high level of efficiency that ensures the successful development of new medication, for example. Alongside microplates for use in pharmaceutical substance testing, the company also provides special plates for immunology, protein crystallisation and DNA analysis.

PRODUCTS FOR THE CRYOPRESERVATION OF SAMPLES

When it comes to freezing and storing samples, Greiner Bio-One has a comprehensive product portfolio consisting of Cryo.s freezing tubes, racks and electronic accessories for opening and closing tubes as well as for sample tracking.

PRODUCTS FOR GENERAL LABORATORY USE AND LIQUID HANDLING

Greiner Bio-One's product portfolio for the variety of activities carried out in laboratories comprises products such as pipettes and pipette tips for handling liquids, as well as small devices that allow work with a wide variety of sample materials.



Microplates for high-throughput screening (HTS)



Cryo.s and biobanking tubes



Sapphire pipette tips

© Greiner Bio-One GmbH 2024 page 22/26



06

FURTHER INFORMATION

© Greiner Bio-One GmbH 2024 page **23**/26

06 FURTHER INFORMATION



ADDITIONAL LINKS

ADDITIONAL LINKS

CONTACT PARTNERS

IMAGES

https://mam.greiner.at/pinaccess/showpin.do?pinCode=m91t2tkV4WWJ

If you require additional images, please get in touch with the press contact for the relevant business division as specified on the following page.

PRESS RELEASES

https://www.gbo.com/en-int/press-events/press

If you require additional information, please get in touch with the press contact for the relevant business division as specified on the following page.

TRADE FAIRS AND EVENTS

https://www.gbo.com/en-int/press-events/events

© Greiner Bio-One GmbH 2024 page 24/26

06 FURTHER INFORMATION



ADDITIONAL LINKS

CONTACT PARTNERS

CONTACT PARTNERS

Mag. Gudrun Miglbauer-Badurek

Director Corporate Communication gudrun.miglbauer-badurek@gbo.com

Julia Franke, MA

Expert Global Communication julia.franke@gbo.com

© Greiner Bio-One GmbH 2024 page 25/26

making a difference

GREINER BIO-ONE INTERNATIONAL GMBH

KREMSMÜNSTER, AUSTRIA

PHONE +43 7583 6791 0 E-MAIL office@gbo.com

www.gbo.com